For Immediate Release
CoLabs Int’l, Corp. proudly announces the appointment of Griffin King as the new CEO. CoLabs Int’l, Corp. is an early mid-stage biotech focused on the development of micro-encapsulate technology which streamlines the safety, delivery and effectiveness of healthcare and agricultural products while having a positive effect on the environment.
Huntington Beach, CA, USA – CoLabs Int’l, Corporation today announces the appointment of Griffin King as its new CEO. Mr. King has had over 15 years of high-level sales and domestic and international marketing experience in aesthetic pharmacology.
Mr. King brings broad aesthetic pharmaceutical experience to the position, having worked previously in senior Management positions globally for Galderma. His global multi-markets experience at Galderma involved successfully developing and expanding sales in numerous product lines. In his various management capacities, Mr. King helped establish strategic decisions relating to global commercial strategies, business services, management targets, sales training, and focused business events.
Mr. King’s focus will be to propel and strategically target CoLabs’ distribution and sales of its technologically advanced products and technology over multiple, global markets.
“We’re confident that Mr. King can guide this company into the future. I can think of no one better than Griffin to lead CoLabs”, said Laura Cohen, M.D., Chairperson of the Board.
Mr. King will assume responsibility of the company effective August 20, 2023.
About CoLabs Int’l, Corp.
CoLabs has developed highly charged microencapsulate technologies that minimize the absorption of chemicals into the body and uncontrolled dispersion of chemicals into the environment.